| Literature DB >> 35670160 |
Minkyung Bae1,2, Kainat Ahmed2, Jung-Eun Yim1,2.
Abstract
Taurine (2-aminoethanesulfonic acid) is a non-essential amino acid mainly obtained through diet in humans. Despite the lack of research on the health effects of taurine in animals and humans, it is widely used as a dietary supplement. Evidence from human and animal studies indicates that taurine is involved in conjugation of bile acids and regulation of blood pressure and has anti-oxidative, anti-inflammatory, and anti-obesogenic properties. Taurine can benefit both human and non-human animal health in multiple ways. However, few interventional and epidemiological studies regarding the beneficial impacts of taurine in humans and other animals have been conducted. Here, we review the evidence from animal and human studies showing that taurine protects against dyslipidemia, obesity, hypertension, and diabetes mellitus.Entities:
Keywords: Diabetes mellitus; Dyslipidemia; Hypertension; Metabolic syndrome; Obesity; Taurine
Year: 2022 PMID: 35670160 PMCID: PMC9284575 DOI: 10.7570/jomes21088
Source DB: PubMed Journal: J Obes Metab Syndr ISSN: 2508-6235
Figure 1Beneficial effects of taurine in humans.
Figure 2Mechanisms underlying the beneficial health effects of taurine. ↓, decrease; ↑, increase; PPAR, peroxisome proliferator-activated receptor; C/EBP, CCAAT/enhancer- binding protein; AP2, adipocyte protein 2; UCP, uncoupling protein; NO, nitric oxide; ACE, angiotensin-converting enzyme; IRS, insulin receptor substrate; AMPK, AMP-activated protein kinase.
Figure 3Taurine and dyslipidemia. CYP7A1, cholesterol 7-hydroxylase; LDLR, low-density lipoprotein receptor; LDL, low-density lipoprotein.
Human studies assessing the association between taurine and various diseases
| Study | Study design | Dosage and intervention | Beneficial effect |
|---|---|---|---|
| Mizushima et al. (1996)[ | 18–29-Year-old male adults (n = 22); randomized control trial (Japan) | High-cholesterol diet accompanied by 6 g of taurine or placebo/day for 3 weeks; Evaluation of total cholesterol, LDL-C, and norepinephrine levels | Taurine supplementation reduced total cholesterol and LDL-C levels. Moreover, it significantly reduced norepinephrine level in the taurine-treated group compared to the placebo group. |
| Liu et al. (2001)[ | Han (n = 775), Tibetan (n = 125), Kazak (n = 204), Uygur (n = 510) subjects aged between 49–54 years; cross-sectional study | NA | A positive correlation between decreased DBP and taurine supplementation was seen in Han and Tibetan subjects, whereas no such correlation was evident in Uygur and Kazak subjects. |
| Milei et al. (1992)[ | 12 Subjects with angina aged 30–60 years; randomized controlled trial | 5 g taurine or placebo 1–3 hours before CABG | Ratio of reperfusion and pre-ischemic sample means was significantly reduced in the taurine group (1.12) compared with the placebo group (2.45) |
| Mizushima et al. (1997)[ | 433 Subjects from Japan and 269 subjects from Brazil aged 45–59 years; cross-sectional study | NA | Hypercholesterolemia prevalence was significantly different between Japanese (5.8%) and Brazilian (28.3%) men, while hypertension was significantly different between Japanese women (14%) and Brazilian women (32.0%); this was attributed to higher consumption of fish high in taurine by Japanese residents. |
| Rosa et al. (2014)[ | 16 Obese and 8 normal weight women (n = 24); randomized double-blind placebo-controlled study | Placebo with 3 g/day starch flour or 3 g/day taurine supplementation | Taurine supplementation restored taurine level in the obese group and decreased markers of inflammation |
| Zhang et al. (2004)[ | Overweight and obese college students (n = 30) aged 20–22 years; double-blind randomization | Taurine 3 g/day or placebo taken orally for 7 weeks | Taurine-supplemented group showed decrease in body weight, TG content, and AI index |
LDL-C, low-density lipoprotein cholesterol; NA, not applicable; DBP, diastolic blood pressure; CABG, coronary artery bypass graft; TG, triglyceride; AI, atherogenic index.
Figure 4Taurine and obesity. ↓, decrease; ↑, increase; UCP, uncoupling protein; PPAR, peroxisome proliferator-activated receptor; C/EBP, CCAAT/enhancer-binding protein; AP2, adipocyte protein 2.
Clinical studies of the mechanisms underlying taurine’s beneficial effects on human health
| Study | Beneficial effect | Mechanism |
|---|---|---|
| Kim and Cha[ | Anti-oxidative effects | Anti-inflammation by neutralization of hypochlorous acid to produce taurine chloramine |
| Schaffer et al. (2016)[ | Energy metabolism | Activates complex l and NADH-sensitive enzymes by reducing the NADH/NAD+ ratio during glycolysis |
| Kadooka et al. (2010)[ | Endoplasmic reticulum stress | Ameliorates brain injury during stroke by inhibiting ER stress |
| Ramila et al. (2015)[ | Ca2+ homeostasis | Taurine depletion leads to cardiomyopathy due to reduced ER Ca2+ ATPase activity |
NADH, nicotinamide adenine dinucleotide hydrogen; ER, endoplasmic reticulum; ATPase, aenosine tri phosphate synthetase.